June 24th 2025
There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.
Depend on Biomarkers, Not Symptoms, for Diagnosis, Early Treatment of GVHD, Experts Argue
May 7th 2025John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.
Read More
Black Patients Have Greater Risk of Dying From GVHD Than White Patients
September 12th 2024The retrospective analysis found Black patients were more likely to develop severe graft versus host disease (GVHD) and have a higher risk of nonrelapse mortality than White patients after hematopoietic stem cell transplantation.
Read More
Biomarkers for Graft-Versus-Host Disease | Part 4
August 11th 2022In this concluding segment of a four-part series, Sophie Paczesny, M.D., Ph.D., of the Hollings Cancer Center of the Medical University of South Carolina and an expert on graft-versus-host disease biomarkers, discusses the future of biomarkers as companion diagnostics.
Read More
Biomarkers for Graft-Versus-Host Disease | Part 2
August 10th 2022Biomarkers can be used for many purposes — diagnosis, prognosis, projections for success of a treatment. Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), reviews a typology of biomarkers that groups them into five subtypes and discusses their use in GVHD.
Read More
Biomarkers for Graft-Versus-Host Disease | Part 1
August 10th 2022What is a biomarker? Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), explains.
Read More
Study: Removing Naïve T Cells is a Promising Strategy for Reducing GVHD
March 8th 2022Results reported in the Journal of Clinical Oncology suggest filtering naïve T cells from peripheral blood stem cell transplants may decrease the risk of chronic graft-versus-host-disease. An accompanying editorial says a randomized trial is needed to provide definitive proof.
Read More